BMO Initiates Neurogene at Outperform With $65 Price Target Neurogene (NGNE) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $44 to $65.(MT...
Source LinkBMO Initiates Neurogene at Outperform With $65 Price Target Neurogene (NGNE) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $44 to $65.(MT...
Source Link
Comments